Biogen Inc. $BIIB Shares Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 153.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,925 shares of the biotechnology company’s stock after buying an additional 31,425 shares during the period. Biogen comprises approximately 1.3% of Privium Fund Management B.V.’s holdings, making the stock its 16th biggest holding. Privium Fund Management B.V.’s holdings in Biogen were worth $7,274,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. Vanguard Group Inc. increased its position in shares of Biogen by 1.5% during the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after acquiring an additional 257,812 shares during the last quarter. State Street Corp increased its holdings in Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after purchasing an additional 71,897 shares during the last quarter. Geode Capital Management LLC increased its holdings in Biogen by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company’s stock worth $490,089,000 after purchasing an additional 71,286 shares during the last quarter. Invesco Ltd. raised its position in shares of Biogen by 2.4% in the 2nd quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company’s stock valued at $291,385,000 after purchasing an additional 55,119 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Biogen during the 2nd quarter valued at approximately $284,358,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Performance

Shares of BIIB stock opened at $179.89 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35. The business has a 50 day moving average of $176.47 and a two-hundred day moving average of $154.62. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $190.20. The company has a market cap of $26.39 billion, a P/E ratio of 16.40, a PEG ratio of 1.47 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The business had revenue of $2.53 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the prior year, the firm earned $4.08 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. As a group, analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BIIB. Mizuho upped their price target on shares of Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a report on Thursday, January 8th. The Goldman Sachs Group reissued a “buy” rating and issued a $225.00 target price on shares of Biogen in a research report on Thursday, January 8th. Robert W. Baird cut their target price on shares of Biogen from $255.00 to $250.00 in a research note on Friday, October 31st. Stifel Nicolaus upgraded Biogen from a “hold” rating to a “buy” rating and lifted their price target for the stock from $144.00 to $202.00 in a research note on Thursday, November 6th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Biogen in a research note on Tuesday, January 13th. Eleven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $192.81.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.